Mouse Anti-CEACAM6 Monoclonal Antibody – Cat# MBS312479

Carcinoembryonic Antigen (CEA) (CEACAM6) Antibody – Mouse Monoclonal

Name: CEACAM6 Antibody; Monoclonal; Mouse; Human-Reactive; MyBioSource
Brand: MyBioSource
SKU: MBS312479
Price: 820 USD
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS312479

MBS312479 is an antibody targeting CEACAM6. Also known as MAb to CEA. Reactive in Human. Host: Mouse. Hybridization of Sp2/0 myeloma cells with spleen cells from BALB/c mice.Source: Ascites. More details

$820 / 1 mg +1 FREE 8GB USB

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Carcinoembryonic Antigen (CEA) (CEACAM6), Monoclonal Antibody

Full Product Name

MAb to CEA

Product Gene Name

anti-CEACAM6 antibody

Product Synonym Names

Monoclonal Antibody to Human Carcinoembryonic Antigen (CEA)

Clonality

Monoclonal

Isotype

IgG1

Host

Host: Mouse. Hybridization of Sp2/0 myeloma cells with spleen cells from BALB/c mice.
Source: Ascites

Species Reactivity

Human

Form/Format

Purified, Liquid

Purity/Purification

>90% pure (SDS-PAGE). Ion exchange chromatography

Specificity

Carcinoembryonic Antigen (CEA)
CEA, epitope specificity group IVa or II. Does not cross react with human leukocytes in cytofluorometry.
Staining in immunohistochemistry:
Brightness - 80
Cytoplasmic staining - 3+
Membrane staining - 2+
Ba

Preparation and Storage

Store at 2 to 8 degree C.

Matching Pairs

Capture Antibody: Carcinoembryonic Antigen (CEA) Clone #B464M (MBS312483)
Detection Antibody: Carcinoembryonic Antigen (CEA) Clone #B459M (MBS312479)

Molecular Weight

15,545 Da

Chromosome Location

chromosome: 19; Location: 19q13.2

3D Structure

ModBase 3D Structure for Q13985

Immunogen

Human natural tumor-derived purified CEA antigen

Affinity Constant

Not determined

Buffer

10mM Tris, pH 7.5 containing 0.15M Sodium chloride

Preservative

0.05% Sodium azide

Important Note

Centrifuge before opening to ensure complete recovery of vial contents.

Warnings

This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1 - 1.0 %. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.

Product Categories/Family for anti-CEACAM6 antibody

Monoclonal Antibodies for Cancer Research

ISO Certification

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Applications Tested/Suitable for anti-CEACAM6 antibody

Immunohistochemistry

Other Notes

Small volumes of anti-CEACAM6 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for CEACAM6. It may not necessarily be applicable to this product.

NCBI GI #

553222

NCBI GeneID

4680

NCBI Accession #

AAA51971.1

UniProt Primary Accession #

Q13985

UniProt Related Accession #

P40199; Q13985; Q14921; Q14922; Q53XP7

NCBI Official Full Name

carcinoembryonic antigen

NCBI Official Synonym Full Names

carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)

NCBI Official Symbol

CEACAM6

NCBI Official Synonym Symbols

NCA; CEAL; CD66c; CEACAM6

UniProt Protein Name

Carcinoembryonic antigen

Protein Family

Carcinoembryonic antigen-related cell adhesion molecule

UniProt Gene Name

CEA

UniProt Entry Name

Q13985_HUMAN

NCBI Protein Information

carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)

NCBI Summary for CEACAM6

Carcinoembryonic antigen (CEA; MIM 114890) is one of the most widely used tumor markers in serum immunoassay determinations of carcinoma. An apparent lack of absolute cancer specificity for CEA probably results in part from the presence in normal and neoplastic tissues of antigens that share antigenic determinants with the 180-kD form of CEA (Barnett et al., 1988 [PubMed 3220478]). For background information on the CEA family of genes, see CEACAM1 (MIM 109770).[supplied by OMIM]

UniProt Comments for CEACAM6

CEACAM6: Belongs to the immunoglobulin superfamily. CEA family

Protein type: Membrane protein, GPI anchor; Membrane protein, integral

Chromosomal Location of Human Ortholog: 19q13.2

Cellular Component: integral to plasma membrane; plasma membrane

Molecular Function: protein binding

Biological Process: cell-cell signaling; signal transduction; blood coagulation; leukocyte migration

Research Articles on CEACAM6

1. CEACAM6-associated signaling pathways could be potential targets for the development of biomarkers to predict the response of patients to adenovirus-based therapies, as well as for the development of more potent adenovirus-based therapeutics
2. Because CEACAM6 acts as an antiapoptotic factor and stabilizes surfactant function, in addition to a putative role in innate defense against bacteria, we propose that it is a multifunctional alveolar protein
3. Data show that desensitization of neutrophils to any two CEACAMs, 1, 3, 6, or 8, results in selective desensitization to those two CEACAMs, while the cells remain responsive to the other two neutrophil CEACAMs.
4. CEACAM6 is overexpressed in borderline and invasive mucinous ovarian neoplasms.
5. findings suggest that CEA (CEACAM5) and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling.
6. All the leukemic samples showed overexpression of CEACAM6 and 8 when compared with normal granulocytes.
7. data support an important role for CEACAM6 in endocrine resistance in breast cancer, which can serve as a powerful predictor of future recurrence
8. Observational study of gene-disease association. (HuGE Navigator)
9. The expression of CEACAM6 in ADH lesions is strongly associated with the development of IBC, therefore, it can be applied as a diagnostic marker either singly or in combination with other marker(s) to predict IBC development in women with ADH lesions.
10. CEACAM6 is a biological tumor marker for epithelial ovarian cancers.
11. the results show that recognition of CEA and CEACAM6, but not CEACAM1, is accompanied by tight attachment to bacteria of cell surface microvilli-like extensions
12. For all tumors, the amount of CEACAM6 expressed was greater than that of CEACAM5, and reflected tumor histotype.
13. CEACAM6 subdomains involved in intercellular adhesion activity and subdomains involved in inhibition of cell differentation are identified and their respective activities are independently blocked.
14. overexpression among human malignancies, immunological targeting of this tumor antigen may have therapeutic applicability
15. Levels of CEACAM6 expression can modulate pancreatic adenocarcinoma cellular invasiveness in a c-Src-dependent manner
16. Data show that variants of Neisseria gonorrhoeae that bind to human carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) 1 and 6 failed to induce detachment and, instead, promoted enhanced host cell adhesion to the ECM.
17. CEACAM6 gene silencing reversed the acquired anoikis resistance of tumor cell lines and inhibited in vivo metastatic ability
18. CEACAM6 is an important determinant of pancreatic adenocarcinoma malignant cellular behavior
19. CD66c is regulated in a manner distinct from other myeloid antigens in childhood lymphoblastic leukemia
20. Overexpression of CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Products associated with anti-CEACAM6 antibody

Reference Product	PubMed Publications
CEACAM1 antibody	>43 publications with CEACAM6 and CEACAM1
CEACAM8 antibody	>16 publications with CEACAM6 and CEACAM8

Diseases associated with anti-CEACAM6 antibody

Disease Name	Pubmed Publications
Neoplasms Antibodies	>66 publications with CEACAM6 and Neoplasms
Adenocarcinoma Antibodies	>23 publications with CEACAM6 and Adenocarcinoma
Inflammation Antibodies	>11 publications with CEACAM6 and Inflammation
Lymphoma Antibodies	>9 publications with CEACAM6 and Lymphoma
Breast Neoplasms Antibodies	>9 publications with CEACAM6 and Breast Neoplasms
Lung Neoplasms Antibodies	>8 publications with CEACAM6 and Lung Neoplasms
Stomach Neoplasms Antibodies	>8 publications with CEACAM6 and Stomach Neoplasms
Leukemia, Myeloid, Acute Antibodies	>8 publications with CEACAM6 and Leukemia, Myeloid, Acute
Necrosis Antibodies	>6 publications with CEACAM6 and Necrosis
Neoplasms, Experimental Antibodies	>4 publications with CEACAM6 and Neoplasms, Experimental

Organs/Tissues associated with anti-CEACAM6 antibody

Organ/Tissue Name	Pubmed Publications
Blood Antibodies	>5621 publications with CEACAM6 and Blood
Lung Antibodies	>1783 publications with CEACAM6 and Lung
Stomach Antibodies	>1037 publications with CEACAM6 and Stomach
Skin Antibodies	>459 publications with CEACAM6 and Skin
Intestine Antibodies	>454 publications with CEACAM6 and Intestine
Pancreas Antibodies	>432 publications with CEACAM6 and Pancreas
Muscle Antibodies	>348 publications with CEACAM6 and Muscle
Kidney Antibodies	>307 publications with CEACAM6 and Kidney
Bladder Antibodies	>248 publications with CEACAM6 and Bladder
Prostate Antibodies	>233 publications with CEACAM6 and Prostate